US Orphan enters distribution deal with UK's IDIS

30 March 2000 20:34  [Source: ICIS news]

HOUSTON (CNI)--Orphan Medical said Thursday it has signed an agreement with the UK's IDIS World Medicines for IDIS to market Orphan products in countries not currently represented.

The distribution agreement involves five Orphan products, including Antizol (fomepizole) and Busulfex (busulfan). Financial terms were not disclosed.

Antizol injections are used as a first line of treatment for ethylene glycol poisoning by the American Academy of Clinical Toxicology (AACT), US poison control centres, and hospital emergency rooms.

Busulfex injections, a new conditioning regimen for bone marrow and stem cell transplants, was approved in the US in 1997 for the treatment of chronic myelogenous leukemia (CML). The drug also has been approved in Canada and Israel.

John Bullion, Orphan chief executive officer, said: "We are encouraged by the number of physicians adopting Busulfex in new studies to optimise the conditioning regimen for the patient's benefit."

IDIS was established in 1987 and works with physicians and regulatory agencies to deliver medicines that have been clinically tested and reviewed. IDIS distributes more than 1000 products annually to more than 40 countries.

Minneapolis, Minnesota-based Orphan also announced Thursday that it has signed an agreement with Germany's Medizinische Handelsgesellschaft (MHG) to market Busulfex. MHG, an international wholesale and importing company headquartered in Frankfurt, works with hospitals and physicians to provide oncology, haematology, immunology and organ transplant products.

By: Kristie Watthuber
+1 713 525 2653

For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.

Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.

Printer Friendly